CompletedPhase 2

Safety and Efficacy Study of BRIMOCHOL™, BRIMOCHOL™ F, and Carbachol in Subjects With Emmetropic Phakic and Pseudophakic Presbyopia

United States18 participantsStarted 2021-03-24

Plain-language summary

Safety and Efficacy Study of BRIMOCHOL™ vs. BRIMOCHOL™ F vs. Carbachol Monotherapy Topical Ophthalmic Solutions in Subjects with Emmetropic Phakic and Pseudophakic Presbyopia

Who can participate

Age range45 Years – 80 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Male or female in good general health * Must have presbyopia Exclusion Criteria: * History of allergic reaction to the study drug or any of its components * Any disease or medical condition that, in the opinion of the Investigator, would prevent the subject from participating in the study or might confound study results

What they're measuring

Proportion of Subjects With a >=15 Letter Gain Without a < 5 Letter Loss in Near Visual Acuity

Timeframe: Day 1, Hour 1 post-dose

Trial details

NCT IDNCT04774237

SponsorVisus Therapeutics

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2021-10-19

Results submitted2024-10-10

View on ClinicalTrials.gov More Presbyopia trials